Immuron Ltd
Research Immuron Ltd (IMRN) on Bullrun: market cap USD 6.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMRN
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.19M
- Financial periodFY2026
- RevenueAUD 7.71M
- Revenue growth5.8%
- Net income-AUD 3.84M
- Gross margin64.6%
Valuation Snapshot
latest market cap is USD 6.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 7.71M | -AUD 3.84M | n/a | 64.6% | -0.52 | AUD 9.02M | n/a | n/a |
| FY2025 | AUD 7.29M | -AUD 5.22M | -AUD 6.14M | 65.4% | -0.91 | AUD 2.83M | AUD 71.86K | AUD 8.07M |
| FY2024 | AUD 4.90M | -AUD 6.94M | -AUD 5.88M | 68.1% | -1.22 | AUD 11.66M | AUD 132.94K | AUD 12.71M |
| FY2023 | AUD 1.80M | -AUD 3.79M | -AUD 2.60M | 72.5% | -0.66 | AUD 17.16M | AUD 189.09K | AUD 19.62M |
| FY2022 | AUD 765.19K | -AUD 2.85M | -AUD 3.16M | 68.4% | -0.5 | AUD 22.11M | AUD 209.79K | AUD 23.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 6.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.35M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 11.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 14.24M | n/a | n/a | n/a |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immuron Ltd's market cap?
Immuron Ltd's market capitalization is USD 6.19M.
What does Immuron Ltd do?
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.